Trials / Active Not Recruiting
Active Not RecruitingNCT06783881
Single-ascending Dose Study of Kylo-12 in Healthy Subjects
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Kylo-12 in Healthy Subjects
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Kylonova (Xiamen) Biopharma co., LTD. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers. Kylo-12 will be evaluated in approximately 50 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Kylo-12 | Administered SC. |
| DRUG | Placebo | Administered SC. |
Timeline
- Start date
- 2025-03-12
- Primary completion
- 2025-12-19
- Completion
- 2026-08-30
- First posted
- 2025-01-20
- Last updated
- 2026-03-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06783881. Inclusion in this directory is not an endorsement.